Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocade (Bortezomib) in Newly Diagnosed Multiple Myeloma
NCT04348006Phase 4Withdrawn
- Sponsor
- Al-Rasheed University College
- Start
- Mar 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Alvocade in multiple myeloma (MM), sponsored by Al-Rasheed University College. Primary endpoints: Assessment the safety of Alvocade® therapy at 6 months and Assessment the effecacy of Alvocade® therapy at 6 months. Planned start Mar 2020; status: withdrawn.
02
Drugs
Alvocade
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04348006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348006.